罗氟司特在国内是否上市？

Chronic non-obstructive pulmonary disease (COPD) is a respiratory disease characterized by airflow limitation. The main symptoms are cough, sputum production, dyspnea and chest tightness. The severity of the disease is related to the degree of chronic inflammatory reaction in the airways and lungs. The mortality rate of patients after onset is high, and it is speculated that COPD may become the third leading cause of death in the world in 2030. The treatment of COPD includes early intervention, stable treatment and acute exacerbation treatment. As an oral phosphodiesterase-4 (PDE-4) inhibitor, it has anti-inflammatory activity. In the 2014 version of the Global Initiative for the Prevention and Treatment of COPD (GOLD) Guidelines, PDE-4 inhibitors are recommended as the second choice for drug treatment of COPD, and the use of such drugs is also recommended in the treatment of acute exacerbations.

For patients with chronic bronchitis, severe to very severe COPD, and a history of acute exacerbations, roflumilast can reduce the incidence of moderate to severe exacerbations requiring steroid treatment by approximately 15% to 20%. Roflumilast combined with long-acting bronchodilators can improve lung function, but its effect on patient-related prognosis, especially in acute exacerbations, is still controversial.

There are no controlled or combined treatment studies of roflumilast and inhaled corticosteroids. Adverse reactions: The most common are nausea, loss of appetite, abdominal pain, diarrhea, sleep disorders and headache, which occur early in treatment, may be reversible and disappear with the extension of treatment time.

Is it listed in China? Currently, roflumilast is not marketed in China and is not eligible for medical insurance. In other words, if patients want to purchase the drug, they must go abroad to purchase it. Traveling abroad to buy medicines is a long journey and requires a lot of manpower and material resources. Coupled with the huge medical expenses, many patient families are overwhelmed. However, according to Medical Companion Travel, 500μg*90 tablets of roflumilast costs approximately $2,850 per box. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about roflumilast, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.